Company
Official Name: Bristol-Myers Squibb Company
Headquarters: New York, NY, United States
Founded: 1887
Employees: 32,200
CEO: Dr. Giovanni Caforio M.D.
$119.95 Billion
USD as of Jan. 1, 2025
Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Merck | $244.44 B |
Roche | $219.35 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | $47.44 B |
EBITDA | $18.41 B |
Gross Profit TTM | $35.99 B |
Profit Margin | -15.30% |
Operating Margin | 18.48% |
Quarterly Revenue Growth | 8.40% |
Bristol-Myers Squibb Company has the following listings and related stock indices.
Stock: NYSE: BMY wb_incandescent
Stock: FSX: BRM wb_incandescent
Stock: XETR: BRM wb_incandescent
Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb
Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)